Comparison of two drugs for epilepsy in children in a clinical trial

Comparison of Efficacy of Levetiracetam and Brivaracetam in Children with Epilepsy with Myoclonic-Atonic Seizures: a randomized controlled trial - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/11/097310

Enrollment

Registered

2025-11-13

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G409- Epilepsy, unspecified

Interventions

Intervention1: Levetiracetam: 20 mg/kg/day daily in two divided doses for 8 weeks Control Intervention1: Brivaracetam: 2 mg/kg/day daily in two divided doses for 8 weeks

Eligibility

Inclusion criteria

Inclusion criteria: 1.Clinical diagnosis of Epilepsy with Myoclonic Atonic Seizures, characterized by myoclonic-atonic seizures with supportive EEG features. 2.Failure to respond adequately to at least one first-line anti-seizure medication (sodium valproate) 3.Minimum baseline seizure frequency of at least 1 myoclonic-atonic seizure per day over the previous 4 weeks.

Exclusion criteria

Exclusion criteria: 1. Prior exposure to either levetiracetam or brivaracetam. 2. Significant hepatic or renal impairment.

Design outcomes

Primary

Measure	Time frame
Proportion of participants with at least 50% reduction in average weekly seizure frequencyTimepoint: At 8 weeks	—

Secondary

Measure	Time frame
Number of clinical seizure-free daysTimepoint: At 8 weeks	—

Countries

India

Contacts

Public ContactDr Prateek Kumar Panda

All India Institute of Medical Sciences, Rishikesh

drprateekpanda@gmail.com9650149735

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026